Liquidia (LQDA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
14.0M
Gross Profit
8.1M
58.00%
Operating Income
-121.3M
-866.63%
Net Income
-130.4M
-931.65%
EPS (Diluted)
-$1.66
Balance Sheet Metrics
Total Assets
230.3M
Total Liabilities
153.0M
Shareholders Equity
77.3M
Debt to Equity
1.98
Cash Flow Metrics
Operating Cash Flow
-101.1M
Free Cash Flow
-101.9M
Revenue & Profitability Trend
Liquidia Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 14.0M | 17.5M | 15.9M | 12.9M | 739.6K |
| Cost of Goods Sold | 5.9M | 2.9M | 2.9M | 3.0M | 237.7K |
| Gross Profit | 8.1M | 14.6M | 13.1M | 9.8M | 501.9K |
| Operating Expenses | 129.4M | 88.0M | 51.8M | 43.6M | 59.6M |
| Operating Income | -121.3M | -73.4M | -38.8M | -33.8M | -59.1M |
| Pre-tax Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
| Income Tax | - | - | - | - | - |
| Net Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
| EPS (Diluted) | -$1.66 | -$1.21 | -$0.67 | -$0.70 | -$1.76 |
Income Statement Trend
Liquidia Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 185.1M | 89.9M | 99.8M | 61.3M | 66.1M |
| Non-Current Assets | 45.2M | 28.4M | 29.4M | 32.5M | 33.5M |
| Total Assets | 230.3M | 118.3M | 129.2M | 93.7M | 99.5M |
| Liabilities | |||||
| Current Liabilities | 41.8M | 18.6M | 8.8M | 7.3M | 11.7M |
| Non-Current Liabilities | 111.3M | 52.5M | 30.0M | 21.1M | 16.7M |
| Total Liabilities | 153.0M | 71.0M | 38.8M | 28.5M | 28.4M |
| Equity | |||||
| Total Shareholders Equity | 77.3M | 47.3M | 90.4M | 65.3M | 71.1M |
Balance Sheet Composition
Liquidia Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
| Operating Cash Flow | -101.1M | -50.8M | -29.4M | -34.8M | -54.2M |
| Investing Activities | |||||
| Capital Expenditures | -4.9M | -1.3M | -587.0K | -107.0K | -752.1K |
| Investing Cash Flow | -4.9M | -1.3M | -587.0K | -107.0K | 247.9K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 191.6M | 42.1M | 63.9M | 26.3M | 63.3M |
| Free Cash Flow | -101.9M | -52.9M | -29.2M | -34.1M | -54.9M |
Cash Flow Trend
Liquidia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.30
Forward P/E
-8.82
Price to Book
23.59
Price to Sales
83.13
PEG Ratio
-8.82
Profitability Ratios
Profit Margin
58.00%
Operating Margin
-1,135.42%
Return on Equity
-203.98%
Return on Assets
-37.66%
Financial Health
Current Ratio
2.93
Debt to Equity
297.04
Beta
0.04
Per Share Data
EPS (TTM)
-$1.71
Book Value per Share
$0.58
Revenue per Share
$0.17
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| lqda | 1.2B | -8.30 | 23.59 | -203.98% | 58.00% | 297.04 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.